Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with ...

Kazia Therapeutics (Nasdaq: KZIA), an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration that accelerated approval for its brain cancer drug, paxalisib ...

SYDNEY - Kazia Therapeutics Limited (NASDAQ: KZIA), a small-cap biotech company ($13.5M market cap) specializing in oncology drug development, has recently concluded discussions with the U.S. Food and ...

1 Day KZIA -41.61% DJIA -0.19% Russell 2K -0.03% Health Care/Life Sciences -0.90% ...

SYDNEY, Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of ...

Australian biotech Kazia Therapeutics (NASDAQ:KZIA) announced Tuesday that the U.S. FDA has indicated that data on overall survival from its GBM-AGILE study data would not be appropriate for ...

Kazia plans to outline a regulatory and clinical path forward for paxalisib by January 2025. Get Real-Time News and Alerts for Your Portfolio Kazia Therapeutics Limited KZIA stock is trading lower ...

Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting ...

SYDNEY - Kazia Therapeutics Limited (NASDAQ: KZIA), a small-cap biotech company ($13.5M market cap) specializing in oncology drug development, has recently concluded discussions with the U.S. Food ...